With the accumulation of post-marketing data concerning concomitant administration of INVIRASE(R) and other drugs, it was found that concomitant use with HIV protease inhibitor
ritonavir (product name: NORVIR(R))caused significant increase of blood INVIRASE(R) concentration.
Study 0452-002 was designed to evaluate the pharmacokinetic profile of multiple doses of SPI-452 and to establish proof of clinical concept of the pharmacokinetic enhancement ability of SPI-452 when combined with either of 2 currently marketed HIV protease inhibitors
, darunavir or atazanavir.
There are numerous examples of marketed drugs that achieve a therapeutic effect by inhibiting protease activity, including HIV protease inhibitors
for the treatment of HIV and AIDS, and angiotensin converting enzyme inhibitors for the treatment of hypertension.
Eliminating the need for ritonavir, which is currently co-administered per label with all once-daily HIV protease inhibitors
to increase their blood levels, could provide significant advantages over current standard-of-care.
The first IND is for SPI-256, an HIV protease inhibitor
in Phase 1 clinical development.
sale and distribution of Fortovase(R), the soft-gel formulation of the HIV protease inhibitor
saquinavir, due to the continued availability of the INVIRASE(R) 500 mg tablet formulation -- a decision previously communicated by the company in mid-2005.
Brecanavir is an HIV protease inhibitor
in Phase IIb clinical development.
We are very happy to have met this important milestone in our lead HIV protease inhibitor
PPL-100 development program, as this allows us to advance this promising drug candidate to the clinical stage.
TSX:PBP), a biotechnology company developing innovative therapeutics in the fields of cancer and HIV/AIDS, announced today results of a one year in vitro resistance selection study showing that its lead HIV protease inhibitor
, PPL- 100, when subjected to a "forced resistance study" showed a potentially high genetic barrier confirming the potential utility of the drug for resistant HIV.
TSX:PBP) today announced preclinical results from its lead HIV protease inhibitor
, PPL-100, development program.
July 19 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated today announced that its collaborator, GlaxoSmithKline (GSK), has received fast track designation for the HIV protease inhibitor
(PI) 640385 (VX-385) from the United States Food and Drug Administration.